ATE322016T1 - Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse - Google Patents
Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisseInfo
- Publication number
- ATE322016T1 ATE322016T1 AT00939629T AT00939629T ATE322016T1 AT E322016 T1 ATE322016 T1 AT E322016T1 AT 00939629 T AT00939629 T AT 00939629T AT 00939629 T AT00939629 T AT 00939629T AT E322016 T1 ATE322016 T1 AT E322016T1
- Authority
- AT
- Austria
- Prior art keywords
- alter
- ability
- directed
- phosphorylation
- circadian rhythm
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Electrophonic Musical Instruments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32774599A | 1999-06-08 | 1999-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322016T1 true ATE322016T1 (de) | 2006-04-15 |
Family
ID=23277866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00939629T ATE322016T1 (de) | 1999-06-08 | 2000-06-07 | Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6555328B1 (de) |
| EP (1) | EP1183541B1 (de) |
| JP (1) | JP4583682B2 (de) |
| KR (1) | KR100722176B1 (de) |
| AT (1) | ATE322016T1 (de) |
| AU (1) | AU767800B2 (de) |
| BR (1) | BR0011437A (de) |
| CA (1) | CA2375450C (de) |
| DE (1) | DE60026998T2 (de) |
| IL (2) | IL146729A0 (de) |
| MX (1) | MXPA01011417A (de) |
| NO (3) | NO330241B1 (de) |
| NZ (1) | NZ514603A (de) |
| WO (1) | WO2000075669A1 (de) |
| ZA (1) | ZA200108962B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476188B1 (en) | 1998-06-19 | 2002-11-05 | The Rockefeller University | Clock gene and methods of use thereof |
| US6436628B1 (en) | 1998-06-19 | 2002-08-20 | The Rockefeller University | Methods of identifying an agent which modulates period and doubletime protein interaction |
| IL146729A0 (en) * | 1999-06-08 | 2002-07-25 | Aventis Pharma Inc | Screening methods for altering circadian rhythm proteins |
| WO2001036618A2 (en) * | 1999-11-18 | 2001-05-25 | Mitsubishi Pharma Corporation | Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced |
| GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| WO2002055667A2 (en) * | 2001-01-11 | 2002-07-18 | Univ Utah Res Found | Identification of an advanced sleep phase syndrome gene in humans |
| WO2004038043A2 (en) * | 2002-10-25 | 2004-05-06 | University Of Surrey | POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS |
| WO2004050841A2 (en) * | 2002-11-27 | 2004-06-17 | University Of Utah Research Foundation | Casein kinase i epsilon and casein kinase i delta and sleep in humans |
| JO2629B1 (en) | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| BRPI0514397A (pt) * | 2004-08-19 | 2008-06-10 | Aventis Pharma Inc | derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon |
| US20100028871A1 (en) * | 2006-05-31 | 2010-02-04 | National Institute Of Radiological Sciences | Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system |
| ES2425179T3 (es) * | 2006-10-25 | 2013-10-11 | The Rockefeller University | Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| CN105744948B (zh) * | 2013-10-14 | 2020-03-24 | 南京大学 | 进食节律提前综合征的识别方法及其应用 |
| KR101600144B1 (ko) * | 2013-12-20 | 2016-03-04 | 서울대학교산학협력단 | 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법 |
| RU2016132574A (ru) | 2014-01-09 | 2018-02-12 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| US11116754B2 (en) | 2015-11-13 | 2021-09-14 | The Trustees Of Columbia University In The City Of New York | Inhibition of TOR complex 2 increases immunity against bacterial infection |
| WO2023129377A1 (en) * | 2022-01-03 | 2023-07-06 | The Johns Hopkins University | Methods and materials for treating heart attack |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157137A (ja) * | 1997-08-28 | 1999-03-02 | Sanyo Bussan Kk | 遊技機用特別図柄表示装置 |
| KR100246893B1 (ko) * | 1997-12-29 | 2000-05-01 | 윤종용 | 전자렌지용 도어 |
| WO1999057137A1 (en) * | 1998-05-07 | 1999-11-11 | The President & Fellows Of Harvard College | Compositions and methods involving regulation of mammalian circadian rhythms |
| IL146729A0 (en) * | 1999-06-08 | 2002-07-25 | Aventis Pharma Inc | Screening methods for altering circadian rhythm proteins |
-
2000
- 2000-06-07 IL IL14672900A patent/IL146729A0/xx active IP Right Grant
- 2000-06-07 KR KR1020017015764A patent/KR100722176B1/ko not_active IP Right Cessation
- 2000-06-07 AT AT00939629T patent/ATE322016T1/de active
- 2000-06-07 NZ NZ514603A patent/NZ514603A/en not_active IP Right Cessation
- 2000-06-07 DE DE60026998T patent/DE60026998T2/de not_active Expired - Lifetime
- 2000-06-07 CA CA002375450A patent/CA2375450C/en not_active Expired - Fee Related
- 2000-06-07 WO PCT/US2000/015633 patent/WO2000075669A1/en active IP Right Grant
- 2000-06-07 EP EP00939629A patent/EP1183541B1/de not_active Expired - Lifetime
- 2000-06-07 MX MXPA01011417A patent/MXPA01011417A/es active IP Right Grant
- 2000-06-07 US US09/589,462 patent/US6555328B1/en not_active Expired - Lifetime
- 2000-06-07 AU AU54689/00A patent/AU767800B2/en not_active Ceased
- 2000-06-07 BR BR0011437-5A patent/BR0011437A/pt not_active Application Discontinuation
- 2000-06-07 JP JP2001501893A patent/JP4583682B2/ja not_active Expired - Fee Related
-
2001
- 2001-10-30 ZA ZA200108962A patent/ZA200108962B/en unknown
- 2001-11-25 IL IL146729A patent/IL146729A/en not_active IP Right Cessation
- 2001-12-06 NO NO20015972A patent/NO330241B1/no not_active IP Right Cessation
-
2010
- 2010-03-23 NO NO20100430A patent/NO20100430L/no not_active Application Discontinuation
- 2010-03-23 NO NO20100431A patent/NO20100431L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000075669A1 (en) | 2000-12-14 |
| DE60026998D1 (de) | 2006-05-18 |
| NO20100431L (no) | 2002-02-05 |
| NZ514603A (en) | 2003-10-31 |
| ZA200108962B (en) | 2003-01-30 |
| BR0011437A (pt) | 2002-03-05 |
| IL146729A0 (en) | 2002-07-25 |
| DE60026998T2 (de) | 2007-04-05 |
| EP1183541B1 (de) | 2006-03-29 |
| IL146729A (en) | 2007-06-17 |
| AU5468900A (en) | 2000-12-28 |
| EP1183541A1 (de) | 2002-03-06 |
| KR100722176B1 (ko) | 2007-05-29 |
| AU767800B2 (en) | 2003-11-27 |
| NO330241B1 (no) | 2011-03-14 |
| NO20100430L (no) | 2002-02-05 |
| NO20015972L (no) | 2002-02-05 |
| NO20015972D0 (no) | 2001-12-06 |
| CA2375450A1 (en) | 2000-12-14 |
| JP4583682B2 (ja) | 2010-11-17 |
| KR20020033101A (ko) | 2002-05-04 |
| JP2003501074A (ja) | 2003-01-14 |
| MXPA01011417A (es) | 2002-06-04 |
| US6555328B1 (en) | 2003-04-29 |
| CA2375450C (en) | 2009-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322016T1 (de) | Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE69918549D1 (de) | Gerät zur feststellung von zahnbelag mittels fluoreszenzmessung | |
| EA200100589A1 (ru) | Азабициклоалканы как модуляторы ccr5 | |
| DE60336298D1 (de) | Medizinische implantierbare vorrichtung zur verminderung der effekten von magnetresonanz | |
| ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| DE69826797D1 (de) | Verfahren zur Generierung von Korrekturtabellen zur Detektion von Fehlzündungen mittels neuronaler Netzwerke | |
| DE60104810D1 (de) | Zellfreies Verfahren zur Herstellung von posttranslational veränderten Proteinen | |
| DE69903410D1 (de) | Entkarbonisierung von gasen unter verwendung von zeolithischen adsorptionsmitteln | |
| CY1105380T1 (el) | Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων | |
| DE69621799D1 (de) | Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| DE69326018D1 (de) | Methoden zur bestimmung der blutplaettchenfunktion | |
| DE60028114D1 (de) | Verfahren zur Analyse von ausgeatmetem Gas | |
| DE59900867D1 (de) | Elektrolyseapparat zur herstellung von halogengasen | |
| DE69606837T2 (de) | Gerät zur Überprüfung der Bestimmungen von klinischen Analysen | |
| DE60217653D1 (de) | Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| DE50212649D1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
| ATE300944T1 (de) | Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen | |
| DE60200713D1 (de) | Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis | |
| ATE312914T1 (de) | Rdgb-proteine | |
| DE69926996D1 (de) | Verwendung von riluzol zur behandlung der retinalischemie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1183541 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |